MESO | Ticker Profile - Titan Protect

MESO

Mesoblast Limited

Healthcare · Biotechnology · NMS

$13.95

Data: 2026-05-28

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 85.7%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$1.9B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-209.43

Based on estimated future earnings — lower means cheaper

Rev Growth

+1,526.8%

Year-over-year revenue change

Profit Margin

-144.3%

How much profit the company keeps from each dollar of revenue

ROE

-18.2%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$35.00

+151% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 2 analysts covering this stock

About Mesoblast Limited

Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers Remestemcel-L, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease and biologic refractory inflammatory bowel disease, as well as ulcerative colitis and Crohn's disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. The company is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy. It has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for the treatment or prevention of chronic heart failure; MPC-25-IC for the treatment or prevention of acute myocardial infarction; and Ryoncil for the treatment of pediatric SR-aGVHD; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa and for the treatment of neonatal hypoxic ischemic encephalopathy; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. The company was incorporated in 2004 and is headquartered in Melbourne, Australia.

https://www.mesoblast.com

Country: Australia Employees: 81 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% PASS

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.769

Good returns relative to risk taken

Kelly Fraction

0.0597

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.686

Acceptable balance between returns and drawdown risk

Annual Return

35.9%

Historical annualised return based on price data

Max Drawdown

-52.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

196

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.79

Less volatile than the market — more defensive

52W High

$21.50

35% below the year high

52W Low

$9.88

41% above the year low

Avg Volume

244,957

Average daily shares traded — higher means easier to buy and sell

Short Ratio

17.0

Days it would take all short sellers to cover — higher means more crowded

Short % Float

3.1%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.70

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

23.52

Heavy leverage — higher financial risk if revenues decline

Current Ratio

1.58

Healthy liquidity position

Quick Ratio

1.35

Like current ratio but excludes inventory — stricter test

Gross Margin

-35.5%

Revenue left after cost of goods — higher means pricing power

Operating Margin

-55.2%

Profit from core operations before interest and tax

Free Cash Flow

$-69,438,336

Negative — the business is spending more than it generates

Revenue (TTM)

$65M

Total revenue over the last 12 months

Net Income

$-94,370,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$35.00

Target Median

$35.00

Target Low

$35.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go